TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice. [electronic resource]
Producer: 20210217Description: 2266-2281.e27 p. digitalISSN:- 1528-0012
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Animals
- Bacteria -- metabolism
- Biomarkers -- blood
- Case-Control Studies
- Cross-Sectional Studies
- Diet, High-Fat
- Dysbiosis
- Fatty Acids, Nonesterified -- metabolism
- Feces -- microbiology
- Female
- Gastrointestinal Microbiome
- Humans
- Intestines -- microbiology
- Lipolysis -- drug effects
- Liver -- drug effects
- Male
- Mice, Inbred C57BL
- Mice, Knockout
- Middle Aged
- Non-alcoholic Fatty Liver Disease -- chemically induced
- Oxidation-Reduction
- Up-Regulation
- Valerates -- blood
- Young Adult
- gamma-Butyrobetaine Dioxygenase -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.